Drugs giant GSK ‘well positioned' to absorb potential US tariffs
GSK reported total sales grew by 4% to £7.52 billion for the first quarter of 2025, compared with a year earlier.
This came on the back of a boost from its speciality medicines division, where sales rose 17% on the back of strong demand for oncology, respiratory and HIV treatments.
It helped to offset another decline in its vaccines arm, where sales dropped by 6% to £2.1 billion for the quarter.
The group said it is on track for turnover to increase by between 3% and 5% over the current year, in line with previous guidance.
It held financial guidance for the year despite uncertainty over US tariffs, with the Trump administration currently investigating whether to change tariff policy for the sector.
GSK chief executive Emma Walmsley said the business is making 'strong progress' (GSK/PA)
'The company is well positioned to respond to the potential financial impact of sector-specific tariffs, should they be implemented, with mitigation options identified in the supply chain and productivity initiatives,' GSK told shareholders on Wednesday.
'The company will continue to monitor and review developments related to this situation.'
GSK was among pharmaceutical firms to recently call on the European Union to allow them to increase prices amid uncertainty over tariffs in the sector, warning Europe it will fall further behind the US without stronger investment incentives.
Chief executive Emma Walmsley said: 'GSK continues to make strong progress, demonstrating the quality, strength and resilience of our portfolio.
'Specialty Medicines, our largest business, delivered strong sales contributions in the quarter and R&D progress continued, with two of the five FDA product approvals expected this year now secured, and the acquisition of a promising new oncology asset.
'This momentum, together with the strength of our portfolio and proven ability to drive operating leverage, underpin our confidence in guidance for the year and our longer-term outlooks.'
Shares in the company were 2% higher in early trading on Wednesday.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
BBC News
4 hours ago
- BBC News
World Business Report How does the EU-US trade deal affect the car industry?
The EU and US clarify details of a tentative trade deal, with President Trump dropping plans for steep tariffs on cars, semi-conductors and pharmaceuticals. We get reaction from the German auto industry. We examine why a gathering of top economists and central bankers in the US is being overshadowed by politics. Tensions are high between President Trump and Federal Chair Jerome Powell, who is preparing a big speech at the Jackson Hole Economic Policy Symposium. And McDonald's gets a scolding from the Japanese government. So why is a Happy Meal campaign involving Pokemon Cards drawing criticism?
North Wales Chronicle
7 hours ago
- North Wales Chronicle
Appeal court throws out massive civil fraud penalty against Donald Trump
The decision came seven months after the Republican returned to the White House. A panel of five judges in New York's mid-level Appellate Division said the verdict, which stood to cost the president more than 515 million dollars (£382 million) and rock his property empire, was 'excessive'. The president, in a social media post, claimed 'total victory', adding: 'I greatly respect the fact that the Court had the Courage to throw out this unlawful and disgraceful Decision that was hurting Business all throughout New York State.' After finding that Mr Trump engaged in fraud by flagrantly padding financial statements that went to lenders and insurers, Judge Arthur Engoron ordered him last year to pay 355 million dollars (£263 million) in penalties. With interest, the sum has topped 515 million dollars. The total — combined with penalties levied on some other Trump Organisation executives including Mr Trump's sons Eric and Donald Jr — now exceeds 527 million dollars (£391 million), with interest. 'While the injunctive relief ordered by the court is well crafted to curb defendants' business culture, the court's disgorgement order, which directs that defendants pay nearly half a billion dollars to the State of New York, is an excessive fine that violates the Eighth Amendment of the United States Constitution,' Judges Dianne T Renwick and Peter H Moulton wrote in one of several opinions shaping the appeals court's ruling. Judge Engoron had also imposed other punishments, such as banning Mr Trump and his two eldest sons from serving in corporate leadership for a few years. Those provisions have been on pause during the appeal, and Mr Trump was able to hold off collection of the money by posting a 175 million dollar (£130 million) bond. The court, which was split on the merits of the lawsuit and the lower court's fraud finding, dismissed the penalty Judge Engoron imposed in its entirety while leaving a pathway for further appeals to the state's highest court, the Court of Appeals. The appeals court, the Appellate Division of the state's trial court, took an unusually long time to rule, weighing Mr Trump's appeal for nearly 11 months after oral arguments last autumn. Normally, appeals are decided in a matter of weeks or a few months. New York attorney general Letitia James, who brought the suit on the state's behalf, had said the businessman-turned-politician engaged in 'lying, cheating and staggering fraud'. In a statement on Thursday, she focused on the part of the case that went her way, saying the court had 'affirmed the well-supported finding of the trial court: Donald Trump, his company and two of his children are liable for fraud'. 'It should not be lost to history: yet another court has ruled that the president violated the law, and that our case has merit,' she added. The president and his co-defendants denied wrongdoing. In a six-minute summation of sorts after a months-long trial, Mr Trump said in January last year that he was 'an innocent man' and the case was a 'fraud on me'. He has repeatedly maintained that the case and verdict were political moves by Ms James and Judge Engoron, who are both Democrats. The Justice Department has subpoenaed Ms James for records related to the lawsuit, among other documents, as part of an investigation into whether she violated the president's civil rights. Her lawyer Abbe D Lowell has said that investigating the fraud case is 'the most blatant and desperate example of this administration carrying out the president's political retribution campaign'. Mr Trump and his lawyers said his financial statements were not deceptive because they came with disclaimers noting they had not been audited. The defence also noted that bankers and insurers independently evaluated the numbers and the loans were repaid. Despite such discrepancies as tripling the size of his Trump Tower penthouse, he said the financial statements were, if anything, low estimates of his fortune. During an appellate court hearing in September, the president's lawyers said many of the case's allegations were too old, a claim they made unsuccessfully before trial. The defence also says Ms James misused a consumer protection law to sue Mr Trump and improperly policed private business transactions that were satisfactory to those involved. State attorneys said the law in question applies to fraudulent or illegal business conduct, whether it targets everyday consumers or big corporations. Though Mr Trump insists no one was harmed by the financial statements, the state says the numbers led lenders to make riskier loans than they knew, and that honest borrowers lose out when others boost their net-worth numbers. The state has argued that the verdict rested on ample evidence and that the scale of the penalty comported with Mr Trump's gains, including his profits on properties financed with the loans and the interest he saved by getting favourable terms offered to wealthy borrowers. The civil fraud case was one of several legal obstacles for Mr Trump as he campaigned, won and started a second term as president.
North Wales Chronicle
7 hours ago
- North Wales Chronicle
Irish leaders welcome clarity on EU-US trade deal and pharma tariffs cap of 15%
Taoiseach Micheal Martin said the trade agreement represented a 'significant win' for the EU while Tanaiste Simon Harris said it offered an 'important shield' for Irish exporters. The EU struck a trade deal with the US on July 27, five days before Mr Trump said a 30% tariff would kick in for the bloc. The deal sees 15% tariffs on most EU goods including cars, semiconductors and pharmaceuticals entering the US. There are 'zero for zero' tariffs on a number of products including aircrafts and aircraft parts, some agricultural goods and certain chemicals – as well as EU purchases of US energy worth 750 billion dollars over three years. In the aftermath of the deal, it was not clear whether 15% would remain the rate for the pharma sector or be increased. The EU-US statement published on Thursday said that as of September 1, the US will apply a maximum tariff rate of 15% on generic pharmaceuticals, their ingredients and chemical precursors. 'The United States intends to promptly ensure that the tariff rate, comprised of the MFN (Most Favored Nation) tariff and the tariff imposed pursuant to Section 232 of the Trade Expansion Act of 1962, applied to originating goods of the European Union subject to Section 232 actions on pharmaceuticals, semiconductors, and lumber does not exceed 15%.' Mr Harris, Ireland's deputy premier and Minister for Foreign Affairs and Trade, welcomed the assurances for the pharmaceutical and semiconductor sectors. 'We welcome clarity that the deal includes a single, all-inclusive 15% tariff on EU goods,' Mr Harris said. 'We also now have assurance that this rate will extend to pharmaceuticals and semiconductors. 'This provides an important shield to Irish exporters that could have been subject to much larger tariffs pending the outcomes of Section 232 US investigations into these sectors.' Mr Harris said this offered a 'first step' to a more 'comprehensive and formal agreement with the US in the future'. 'Our intention now is to see what other carve outs can be made in areas of interest for Irish exporters.' Irish premier Micheal Martin said the statement brought 'greater clarity and certainty' to what the EU-US agreement would mean in practice. 'This is especially important for enterprises that either import from or export to the US,' he said. 'Given the scale of the pharmaceutical and semiconductor sectors in Ireland, it is important that the Joint Statement confirms that 15% is a ceiling that will apply to EU exports in these areas in all circumstances, including when the current US Section 232 investigations are concluded. 'While I have been clear all along that I do not support tariffs, this is a significant win for the EU. 'Given the significance of the airline sector to Ireland, a specific carve-out for aircraft and aircraft parts is also welcome. 'There are areas where further work remains to be done, including a potential carve-out for med-tech products and spirits. 'I hope this will be advanced as quickly as possible. We will continue to advocate for these sectors given their significant importance to our domestic economy.' Paul Sweetman, chief executive of the American Chamber of Commerce Ireland, welcomed the joint statement as providing 'greater clarity to business on the future of the transatlantic trading partnership, worth over four billion dollars daily'. 'The framework brings more certainty and allows for further work to grow our mutually beneficial economic relationship,' he said. 'In supporting the US-Ireland and US-EU trading relationships into the future, we must also focus on enhancing competitiveness. 'Now is the time to make smart policy and investment decisions to deliver critical infrastructure projects, meet future skills needs, bolster our RD&I ecosystem, and secure Ireland's position as a digital regulatory hub. 'AmCham will continue to work closely with the Irish Government, the US administration and our EU and US partners in growing investment on both sides of the Atlantic.'
